- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Schering-Plough expands sales
Schering-Plough Corp., Madison, NJ, has announced the launch of a new, 120-member primary care sales force to complement its existing hepatitis C sales team. The new force is being acquired from Triangle Park, NC-based Innovex.
Schering-Plough Corp., Madison, NJ, has announced the launch of a new, 120-member primary care sales force to complement its existing hepatitis C sales team. The new force is being acquired from Triangle Park, NC-based Innovex.
Prior to the announcement, Schering-Plough's hepatitis C sales force called solely on gastroenterologists, but because primary care physicians are becoming a more integral part of diagnosing, referring and treating infectious diseases, Schering-Plough said the new group will target the physician community directly.
According to the American Academy of Family Physicians, there are nearly 80,000 primary care physicians practicing in the United States, providing treatment for hundreds of thousands of patients each year. Only a fraction of the estimated four million Americans infected with the hepatitis C virus have been identified. Since one in 50 adult Americans are infected with hepatitis C, it is probable that PCPs are seeing patients who have yet to be diagnosed. According to Schering-Plough, the fact that most patients visit their primary care physicians to address unidentified ailments or for complete physicals makes it important that PCPs are kept informed of up-to-date statistics and therapeutic advances in the treatment of hepatitis C.
Jeff Meehan, national manager of Schering-Plough's hepatitis C primary care sales force, said: "Our goal is to arm the primary care physicians with more in-depth knowledge regarding diagnosis and current treatments for hepatitis C." PR
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
To Tackle the Plastic Waste Crisis in Pharma, Here’s Where to Start
October 30th 2024By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.
